NCT00289549

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Phase II Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: BioCryst Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy (28 days).

Conditions

• Leukemia, Lymphocytic, Chronic

Interventions

Type	Name	Description
DRUG	forodesine hydrochloride (BCX-1777)	experimental, forodesine oral dose 200 mg administered daily.

Timeline

• Start date: 2005-06-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2006-02-10
• Last updated: 2012-02-08

Locations

1 site across 1 country: United States